EDGEWISE THERAPEUTICS INC (EWTX)
US28036F1057 - Common Stock
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
Commit To Buy Edgewise Therapeutics At $12.50, Earn 22.1% Annualized Using Options
Commit To Purchase Edgewise Therapeutics At $12.50, Earn 19.2% Annualized Using Options
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
Edgewise Therapeutics Non-GAAP EPS of $0.47 (NASDAQ:EWTX)
Edgewise Therapeutics, a pharmaceutical company, reports Q4 Non-GAAP EPS of $0.47 and holds cash reserves of $318.4 million as of December 31, 2023.
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Krystal Biotech, Candel, Edgewise gain on FDA fast track tags (NASDAQ:KRYS)
Krystal Biotech (KRYS), Candel Therapeutics (CADL), and Edgewise Therapeutics (EWTX) are among latest to win fast-track designations from the U.S. FDA. Read more here.
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
Insider Favorites: 7 Stocks with Bullish Buying Signals
Although you’ll still want to conduct your due diligence, following the smart money into these insider favorite stocks is tempting.
Edgewise Therapeutics stock rises after it prices its 21.8M offering (NASDAQ:EWTX)
Edgewise Therapeutics (EWTX) saw a 17.65% rise in pre-market trade after pricing its offering, with shares at $11.00 apiece for gross proceeds of ~$240M.
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
Analysts have high hopes for these three innovation companies in 2024.
Commit To Purchase Edgewise Therapeutics At $7.50, Earn 6.7% Annualized Using Options
Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
Friday 12/29 Insider Buying Report: MACK, EWTX
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
Speculator’s Watch List: 7 Stocks Ripe for a Short-Squeeze Windfall
Although betting against the bears is risky, the rewards for targeting short-squeeze stocks can also be stratospheric.
Edgewise Therapeutics GAAP EPS of -$0.41 (NASDAQ:EWTX)
Edgewise Therapeutics reports Q3 2023 financial results with a GAAP EPS of -$0.41.
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Edgewise Therapeutics to Present at Upcoming Investor Conferences
Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
